Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer

Abstract

Purpose

To evaluate the differences in patterns of recurrence and treatment results by histology after definitive radiotherapy for stage III non-small cell lung cancer (NSCLC) in Japan.

Materials and methods

Patients with stage III NSCLC who underwent definitive radiotherapy between 2000 and 2016 in our institution were included. A total of 217 patients were enrolled. Propensity score matching was used to exclude the following confounding factors: (1) age (≥70 years or <70 years), (2) gender, (3) T factor, (4) N factor, (5) Eastern Cooperative Oncology Group performance status score and (6) smoking status (Brinkman index ≥400 or <400).

Results

The median observation period for survivors was 55.1 months. After propensity score matching, the Sqcc and adenocarcinoma groups each included 62 paired patients. There was no significant difference in OS or PFS between the adenocarcinoma and Sqcc groups. However, rates of recurrence in the GTV-primary site (p = 0.009) and GTV-lymph node site (p = 0.037) were significantly higher in patients with Sqcc than in patients with adenocarcinoma. New metastatic recurrence was more frequent in patients with adenocarcinoma than in patients with Sqcc (p = 0.025).

Conclusion

There were significant differences in patterns of recurrence after definitive (chemo)radiotherapy between patients with Sqcc and patients with adenocarcinoma.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Aupérin A, Le Péchoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2181–90.

    Article  Google Scholar 

  2. 2.

    Yoon SM, Shaikh T, Hallman M. Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 2017;8(1):1–20.

    CAS  Article  Google Scholar 

  3. 3.

    Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, et al. Long-term results of nrg oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J Clin Oncol. 2020;38(7):706–14.

    CAS  Article  Google Scholar 

  4. 4.

    Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA, et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e314S-e340S.

    CAS  Article  Google Scholar 

  5. 5.

    Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 2010;28(20):3299–306.

    CAS  Article  Google Scholar 

  6. 6.

    Yamamoto N, Nakagawa K, Nishimura Y, Tsujino K, Satouchi M, Kudo S, et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol. 2010;28(23):3739–45.

    Article  Google Scholar 

  7. 7.

    Jouglar E, Isnardi V, Goulon D, Ségura-Ferlay C, Ayadi M, Dupuy C, et al. Patterns of locoregional failure in locally advanced non-small cell lung cancer treated with definitive conformal radiotherapy: results from the Gating 2006 trial. Radiother Oncol. 2018;126(2):291–9.

    Article  Google Scholar 

  8. 8.

    Rajpara RS, Schreibmann E, Fox T, Stapleford LJ, Beitler JJ, Curran WJ, et al. Locoregional tumor failure after definitive radiation for patients with stage III non-small cell lung cancer. Radiat Oncol. 2014;9:187.

    Article  Google Scholar 

  9. 9.

    Schytte T, Nielsen TB, Brink C, Hansen O. Pattern of loco-regional failure after definitive radiotherapy for non-small cell lung cancer. Acta Oncol. 2014;53(3):336–41.

    Article  Google Scholar 

  10. 10.

    van Diessen JN, Chen C, van den Heuvel MM, Belderbos JS, Sonke JJ. Differential analysis of local and regional failure in locally advanced non-small cell lung cancer patients treated with concurrent chemoradiotherapy. Radiother Oncol. 2016;118(3):447–52.

    Article  Google Scholar 

  11. 11.

    Senthi S, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. Lancet Oncol. 2012;13(8):802–9.

    Article  Google Scholar 

  12. 12.

    Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3(1):46–52.

    Article  Google Scholar 

  13. 13.

    Harris JP, Murphy JD, Hanlon AL, Le QT, Loo BW Jr, Diehn M. A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014;88(4):872–84.

    Article  Google Scholar 

  14. 14.

    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16(2):187–99.

    CAS  Article  Google Scholar 

  15. 15.

    Abel S, Hasan S, Verma V, Weksler B, Colonias A, Horne ZD, et al. Establishing a histology-specific biologically effective dose threshold for lung stereotactic ablative radiotherapy (SABR): is ≥100 Gy(10) enough? Lung Cancer. 2019;135:169–74.

    Article  Google Scholar 

  16. 16.

    Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, et al. Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: long-term follow-up of a large patient cohort. Lung Cancer. 2018;117:14–9.

    Article  Google Scholar 

  17. 17.

    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342–50.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Keiichi Jingu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics statement

All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. This study was approved by our institutional review board (2017-1-119).

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Katagiri, Y., Jingu, K., Yamamoto, T. et al. Differences in patterns of recurrence of squamous cell carcinoma and adenocarcinoma after radiotherapy for stage III non-small cell lung cancer. Jpn J Radiol (2021). https://doi.org/10.1007/s11604-021-01091-y

Download citation

Keywords

  • Patterns of recurrence
  • Non-small cell lung cancer
  • Chemoradiotherapy
  • Histology